<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01065103</url>
  </required_header>
  <id_info>
    <org_study_id>H09-03435</org_study_id>
    <nct_id>NCT01065103</nct_id>
  </id_info>
  <brief_title>Fractional Flow Reserve (FFR) Stability in Non-Culprit Vessels at ST Elevation Myocardial Infarction(STEMI)</brief_title>
  <official_title>Fractional Flow Reserve Stability Study of Non-culprit Vessels in Patients With ST Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiology Research UBC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardiology Research UBC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been shown that if it can be accomplished within a 90 minute &quot;door to balloon&quot; time,
      opening an artery in an acute heart attack situation (ST elevation myocardial infarction or
      STEMI) is best treated with balloon angioplasty and stenting (percutaneous coronary
      intervention or PCI). In these situations, there may be narrowings other than the one causing
      the heart attack (culprit) and studies have shown that delaying treatment of other narrowings
      for follow-up procedure is better than intervening at the time of the acute MI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prompt, sustained and complete reperfusion of the myocardium supplied by the infarct related
      artery (IRA) remains the cornerstone of therapy for the treatment of ST segment elevation
      myocardial infarction (STEMI). Although reperfusion can be achieved using fibrinolytic
      agents, it is generally accepted that primary percutaneous coronary intervention (PPCI) is
      preferable, with the caveat that it be performed promptly by experienced personnel.

      It has been observed that up to 74% of patients with STEMI have evidence of multi-vessel
      disease (MVD) during angiography. The presence of MVD is independently associated with worse
      clinical outcomes and the presence of MVD at the time of STEMI is predictive of the need for
      future revascularization within 1 year, with over half of these repeat procedures driven by
      the development of unstable coronary syndromes 8. However, retrospective analyses have
      determined that immediate intervention upon non-culprit vessels (NCV) in addition to the IRA
      is associated with worse clinical outcomes compared to a strategy of intervening upon the IRA
      alone. Furthermore, small studies have shown no increase in mortality associated with a
      strategy with delayed (7 day) intervention of NCV compared to a strategy of intervening on
      the IRA alone. Accordingly, it is considered inappropriate to intervene upon non-culprit
      arteries in the absence of demonstrable ischemia following successful revascularization of
      the IRA in the setting of STEMI 11 and the 2007 ACC/AHA STEMI guidelines give a Class IIb
      recommendation for delayed intervention upon a hemodynamically significant NCV &gt;24 hours
      after the index STEMI.

      However, the guidelines do not provide guidance regarding how to define hemodynamic
      significance of the NCV, nor do they speak to the exact timing of when NCV revascularization
      should be performed after the initial 24 hours. Indeed, this ambiguity is reflected in local
      practice within the Vancouver Coastal Health Authority (R. Boone, personal communication),
      with some interventional cardiologists performing NCV revascularization during the index
      hospitalization prior to patient discharge, while others bring patients back within 6-8 weeks
      of the index STEMI for a &quot;staged&quot;, elective revascularization of the NCV. Finally, other
      cardiologists will defer NCV revascularization entirely in the absence of recurrent ischemia.

      There remains significant doubt as to the most appropriate treatment strategy for the STEMI
      patient who is found to have MVD. Unfortunately, this clinical dilemma is made more difficult
      by the observation that the angiographic and clinical assessment of the NCV remains imprecise
      in the STEMI setting. It remains unclear whether or not traditional angiographic assessment
      of the NCV is reliable over time following an index myocardial infarction, or if it can be
      used to reliably guide decision making for revascularization of NCV in the setting of STEMI.
      In one study, only 10% of lesions judged by visual assessment of the coronary angiogram to
      require NCV PCI following STEMI, were noted to be angiographically significant by
      quantitative coronary angiography at the time of the index angiogram 12. Finally, prior
      studies have demonstrated that the severity of non culprit lesions were found to be
      significantly exaggerated using traditional angiography at the time of the index MI. A study
      of 548 patients with acute MI and MVD revealed that 21% of NCV lesions initially thought to
      be &gt;50% at the time of the index MI were found to be &lt;50% at the time of subsequent
      angiography. Accordingly, there is significant interest in finding alternate means of
      assessing clinically and angiographically significant lesions in the setting of both stable
      and unstable coronary syndromes.

      Fractional flow reserve (FFR) is a simple, reliable and reproducible physiological index of
      lesion severity. It is defined as the ratio between coronary artery pressure distal to a
      stenosis and aortic root pressure, measured following maximal dilation of the distal coronary
      resistance vessels. FFR is a reliable index of maximal achievable coronary flow. An FFR of
      &lt;0.8 identifies ischemia-causing coronary stenoses with &gt;90% accuracy. Conversely, lesions
      deemed nonsignificant by FFR can be safely treated medically with an annual rate of death or
      myocardial infarction of &lt;1%. Recently, an FFR guided strategy for elective PCI was found to
      be superior to a strategy of coronary intervention guided by angiography alone. FFR has also
      been found to be a reliable modality for the hemodynamic assessment of coronary lesions in
      the setting of acute myocardial infarction, with a similar correlation between FFR and
      percent diameter stenosis of coronary vessels in the acute infarct setting compared to FFR
      amongst matched controls undergoing elective PCI. Additionally, FFR correlates well with the
      identification of residual reversible perfusion abnormalities shortly following an index
      myocardial infarction (MI). However, it remains unknown if an abnormal FFR of a NCV remains
      stable following an acute STEMI.

      We are proposing a study to determine the precision and stability of FFR as a measure of
      lesion severity in NCV in patients undergoing clinically indicated revascularization of the
      culprit vessel in the setting of STEMI. Our hypothesis is that FFR will remain stable over
      time within myocardium that is not subtended by the infarct related artery. We believe FFR
      can potentially serve as a reliable and safe angiographic tool to guide delayed
      revascularization decisions for non-culprit vessels amongst STEMI patients with MVD.

      STUDY SCHEMA Following successful revascularization of the IRA, patients deemed to be
      appropriate for a delayed revascularization procedure on a NCV (ie not during the index
      hospitalization) will undergo FFR of the NCV during the index catheterization. Consent for
      the FFR will be obtained prior to successful revascularization of the IRA. Patients with NCV
      stenoses who are brought back for planned elective revascularization of the NCV lesion(s),
      according to usual clinical practice following revascularization of the culprit lesion, will
      undergo repeat FFR on the NCV prior to planned revascularization. Patients who are deemed
      appropriate to undergo intervention on the NCV during the index hospitalization for clinical
      reasons will not be eligible for inclusion in this analysis.

      ENDPOINTS The primary endpoint of this study will be the comparison of initial and repeat FFR
      of a NCV amongst STEMI patients with MVD deemed appropriate for delayed revascularization of
      the NCV. This study will not stipulate the timing of NCV revascularization; this decision
      will be made by the treating interventional cardiologist. However it is expected that most
      patients will undergo NCV revascularization within 4 to 8 weeks following the index hospital
      stay. Patients who require in-hospital revascularization of the NCV during the index
      hospitalization will not be enrolled into this study. Secondary endpoints of the trial will
      be the comparison of baseline and repeat FFR with digital subtraction quantitative
      angiography of the NCV. Tertiary endpoints will be the evaluation of major adverse cardiac
      events amongst enrolled patients through to the repeat procedure.

      CLINICAL IMPACT We believe that the results of this proposed study could result in
      significant changes in the management of STEMI. A potential finding that FFR is a durable
      method of assessing the severity of the NCV in the setting of STEMI could lead to a shift
      towards the use of this technology to guide decision making for revascularization in acute
      coronary syndromes, similar to the paradigm shift seen in elective PCI following the
      publication of the FAME trial. Furthermore, our study will expand upon our understanding of
      the angiographic behaviour of nonculprit vessels in the setting of STEMI, which may serve to
      change future recommendations regarding revascularization decisions amongst patients with MVD
      who present with acute myocardial infarction
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FFR measurement</measure>
    <time_frame>Baseline and repeated at 4-6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>FFR measurement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FFR (Fractional Flow Reserve)</intervention_name>
    <description>Single FFR measurement in non-culprit vessel</description>
    <arm_group_label>FFR measurement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any patient &gt;18 years of age with an acute STEMI eligible for primary PCI

          2. Readily identifiable culprit vessel and at least one other (non-culprit) vessel of a
             least &gt;50% severity by traditional angiography

          3. Deemed appropriate for a strategy of delayed revascularization of the NCV.

        Exclusion Criteria:

          1. Inability to provide informed consent

          2. Cardiogenic shock or severe (Killip III) congestive heart failure

          3. Hemodynamically significant ventricular arrhythmias

          4. Severe recurrent clinically significant ischemia following successful PCI of the IRA

          5. Thrombocytopenia (platelet count &lt;100,000)

          6. Severe anemia (HgB &lt;100 g/L)

          7. Major bleeding during hospitalization of the index STEMI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology; American Heart Association, Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr, Anbe DT, Kushner FG, Ornato JP, Pearle DL, Sloan MA, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008 Jan 15;51(2):210-47. doi: 10.1016/j.jacc.2007.10.001. Review. Erratum in: J Am Coll Cardiol. 2008 Mar 4;51(9):977.</citation>
    <PMID>18191746</PMID>
  </reference>
  <reference>
    <citation>Keeley EC, Grines CL. Primary percutaneous coronary intervention for every patient with ST-segment elevation myocardial infarction: what stands in the way? Ann Intern Med. 2004 Aug 17;141(4):298-304. Review.</citation>
    <PMID>15313746</PMID>
  </reference>
  <reference>
    <citation>Keeley EC, Grines CL. Should patients with acute myocardial infraction be transferred to a tertiary center for primary angioplasty or receive it at qualified hospitals in the community? The case for emergency transfer for primary percutaneous coronary intervention. Circulation. 2005 Nov 29;112(22):3520-32; discussion 3533.</citation>
    <PMID>16320379</PMID>
  </reference>
  <reference>
    <citation>Koyama Y, Hansen PS, Hanratty CG, Nelson GI, Rasmussen HH. Prevalence of coronary occlusion and outcome of an immediate invasive strategy in suspected acute myocardial infarction with and without ST-segment elevation. Am J Cardiol. 2002 Sep 15;90(6):579-84.</citation>
    <PMID>12231080</PMID>
  </reference>
  <reference>
    <citation>Hanratty CG, Koyama Y, Rasmussen HH, Nelson GI, Hansen PS, Ward MR. Exaggeration of nonculprit stenosis severity during acute myocardial infarction: implications for immediate multivessel revascularization. J Am Coll Cardiol. 2002 Sep 4;40(5):911-6.</citation>
    <PMID>12225715</PMID>
  </reference>
  <reference>
    <citation>Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med. 2000 Sep 28;343(13):915-22.</citation>
    <PMID>11006367</PMID>
  </reference>
  <reference>
    <citation>Corpus RA, House JA, Marso SP, Grantham JA, Huber KC Jr, Laster SB, Johnson WL, Daniels WC, Barth CW, Giorgi LV, Rutherford BD. Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction. Am Heart J. 2004 Sep;148(3):493-500.</citation>
    <PMID>15389238</PMID>
  </reference>
  <reference>
    <citation>Glaser R, Selzer F, Faxon DP, Laskey WK, Cohen HA, Slater J, Detre KM, Wilensky RL. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation. 2005 Jan 18;111(2):143-9. Epub 2004 Dec 27.</citation>
    <PMID>15623544</PMID>
  </reference>
  <reference>
    <citation>Kong JA, Chou ET, Minutello RM, Wong SC, Hong MK. Safety of single versus multi-vessel angioplasty for patients with acute myocardial infarction and multi-vessel coronary artery disease: report from the New York State Angioplasty Registry. Coron Artery Dis. 2006 Feb;17(1):71-5.</citation>
    <PMID>16374145</PMID>
  </reference>
  <reference>
    <citation>Chen LY, Lennon RJ, Grantham JA, Berger PB, Mathew V, Singh M, Holmes DR Jr, Rihal CS. In-hospital and long-term outcomes of multivessel percutaneous coronary revascularization after acute myocardial infarction. Am J Cardiol. 2005 Feb 1;95(3):349-54.</citation>
    <PMID>15670543</PMID>
  </reference>
  <reference>
    <citation>Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA; American College of Cardiology Foundation Appropriateness Criteria Task Force; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Thoracic Surgery; American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography; Heart Failure Society of America; Society of Cardiovascular Computed Tomography. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: a report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2009 Feb 10;53(6):530-53. doi: 10.1016/j.jacc.2008.10.005.</citation>
    <PMID>19195618</PMID>
  </reference>
  <reference>
    <citation>Lemesle G, de Labriolle A, Bonello L, Torguson R, Kaneshige K, Xue Z, Suddath WO, Satler LF, Kent KM, Lindsay J, Pichard AD, Waksman R. Incidence, predictors, and outcome of new, subsequent lesions treated with percutaneous coronary intervention in patients presenting with myocardial infarction. Am J Cardiol. 2009 May 1;103(9):1189-95. doi: 10.1016/j.amjcard.2009.01.029. Epub 2009 Mar 13.</citation>
    <PMID>19406257</PMID>
  </reference>
  <reference>
    <citation>Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek J Koolen JJ, Koolen JJ. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med. 1996 Jun 27;334(26):1703-8.</citation>
    <PMID>8637515</PMID>
  </reference>
  <reference>
    <citation>De Bruyne B, Pijls NH, Bartunek J, Kulecki K, Bech JW, De Winter H, Van Crombrugge P, Heyndrickx GR, Wijns W. Fractional flow reserve in patients with prior myocardial infarction. Circulation. 2001 Jul 10;104(2):157-62.</citation>
    <PMID>11447079</PMID>
  </reference>
  <reference>
    <citation>Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van't Veer M, BÃ¤r F, Hoorntje J, Koolen J, Wijns W, de Bruyne B. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol. 2007 May 29;49(21):2105-11. Epub 2007 May 17.</citation>
    <PMID>17531660</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2010</study_first_submitted>
  <study_first_submitted_qc>February 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2010</study_first_posted>
  <last_update_submitted>September 8, 2014</last_update_submitted>
  <last_update_submitted_qc>September 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardiology Research UBC</investigator_affiliation>
    <investigator_full_name>David Wood, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>Primary angioplasty</keyword>
  <keyword>Non-culprit vessel at STEMI</keyword>
  <keyword>Fractional Flow Reserve</keyword>
  <keyword>ST-elevation myocardial infarction</keyword>
  <keyword>Fractional Flow Reserve in non-culprit vessel at STEMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

